Progress with thiazolidinediones in the management of type 2 diabetes mellitus
- 1 February 2004
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 26 (2) , 177-190
- https://doi.org/10.1016/s0149-2918(04)90017-3
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic PatientsJournal of Clinical Endocrinology & Metabolism, 2002
- Clinical evidence of thiazolidinedione‐induced improvement of pancreatic β‐cell function in patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2002
- Metabolic and Additional Vascular Effects of ThiazolidinedionesDrugs, 2002
- New drug targets for type 2 diabetes and the metabolic syndromeNature, 2001
- PPARγ and the Treatment of Insulin ResistanceTrends in Endocrinology & Metabolism, 2000
- Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes Care, 2000
- Thiazolidinediones Down-Regulate Plasminogen Activator Inhibitor Type 1 Expression in Human Vascular Endothelial Cells: A Possible Role for PPARγ in Endothelial FunctionBiochemical and Biophysical Research Communications, 1999
- RosiglitazoneDrugs, 1999
- Inhibition of oxidation of low density lipoprotein by troglitazoneAtherosclerosis, 1996
- Pathogenesis of NIDDM: A Balanced OverviewDiabetes Care, 1992